SABCS 2022 | Maintenance w/ ET + ribociclib after 1L chemotherapy in HR+/HER2- metastatic breast cancer

Sibylle Loibl, MD, PhD, German Breast Group, Neu-Isenburg, Germany, provides an overview of the AMICA (NCT03555877) trial investigating maintenance therapy with endocrine therapy and ribociclib after first-line chemotherapy in hormone receptor (HR)-positive/HER2-negative metastatic breast cancer. The primary objective was to estimate the median progression-free survival (PFS) of patients treated with endocrine therapy plus ribociclib and secondary objectives include median overall-survival (OS), safety, compliance, clinical benefit rate (CBR) and patient reported outcomes. The results will be presented at the San Antonio Breast Cancer Symposium (SABCS) 2022. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.